Case ReportJournal of Pharmacology and PharmacotherapeuticsVol. 6 | Issue 3 | 2015 | pp. 175–178Open access
Complete resistance after maximal dose of rocuronium
- 1*,
- 1,
- 1,
- 1,
- 2,
- 3,
- 3
- 1 Department of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Italy.
- 2 Department of Anesthesia and Intensive Care, San Salvatore Hospital, L’Aquila, Italy.
- 3 Department of Anesthetic, Surgical, and Emergency Science ‑ Intensive Care Unit, Second University of Naples, Naples, Italy.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Annalisa Capuano
Department of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Italy.
Copyright: © 2015 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2015
- Received:
- Jul 17, 2014
- Accepted:
- Dec 21, 2014
How to cite
Capuano, A., Sullo, M. G., Rafaniello, C., Sportiello, L., Fusco, P., Vizia, M. D., & Ferraro, F. (2015). Complete resistance after maximal dose of rocuronium. Journal of Pharmacology and Pharmacotherapeutics, 6(3), 175–178. https://doi.org/10.4103/0976-500X.162012
Abstract
Rocuronium is a non‑depolarizing neuromuscular blocking agent (NDNMBA), employed in the clinic as an adjunct to general anesthesia to facilitate tracheal intubation rapid sequence, and to provide skeletal muscle relaxation during surgery. Many cases of resistance to neuromuscular blocking agents (NMBAs) have been anecdotally reported. There are specific pathologic states, such as upper motor neuron lesions, severe thermal injuries, liver disease, renal failure, disuse atrophy, all of which show an increased resistance to the effects of nondepolarizing muscle relaxants. Also concurrent drug therapy can alter the efficacy of NMBAs such as some classes of antibiotics, furosemide, β receptor agonists, phosphodiesterase inhibitors, calcium antagonists, respiratory stimulants but also ketamine, propofol and barbiturates at high concentrations. In this scenario we describe an unusual case of 20‑years‑old man who showed a complete resistance to rocuronium maybe due to a glucocorticoids concomitant therapy.
Keywords
Subject
Article metadata
| Title | Complete resistance after maximal dose of rocuronium |
|---|---|
| Authors | Annalisa Capuano; Maria Giuseppa Sullo; Concetta Rafaniello; Liberata Sportiello; Pierfrancesco Fusco; Macella De Vizia; Fausto Ferraro |
| Affiliations | Department of Experimental Medicine, Section of Pharmacology, Pharmacoepidemiology and Pharmacovigilance Center of the Campania Region, Second University of Naples, Italy.; Department of Anesthesia and Intensive Care, San Salvatore Hospital, L’Aquila, Italy.; Department of Anesthetic, Surgical, and Emergency Science ‑ Intensive Care Unit, Second University of Naples, Naples, Italy. |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 6, Issue 3 (2015) |
Also in this issue
- Are we moving towards a new definition of essential medicines?pp. 123–5
- Inhaled insulin: A “puff” than a “shot” before mealspp. 126–129
- Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndromepp. 130–135
- Inhibition by sildenafil of contractility of isolated non‑pregnant human myometriumpp. 136–141
- Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical studypp. 142–146
Readers Also Viewed
Development and Validation of UV/visible Spectrophotometric Method for Estimation of Piroxicam from Bulk and Formulation
Sandip Mohan Honmane, Kunal Rajaram Yadav, Yuvraj Dilip Dange
Apr 23, 2025
Effects of Artificial Intelligence on Academic Performance of Library and Information Science University Students: A Meta-Analysis (2023-2025)
Kayode Sunday John Dada
Aug 6, 2026
Bridging Innovation and Impact: A Multidisciplinary Approach to Contemporary Research Challenges
Mueen Ahmed KK
Aug 11, 2026